Puesta al día en adultos y niños | 02 AGO 21

Migraña

Actualización sobre patogenia, tratamiento y prevención de la migraña aguda
Autor/a: Messoud Ashina N Engl J Med 2020;383:1866-76
INDICE:  1. Texto principal | 2. Referencias bibliográficas
Referencias bibliográficas

1. Stovner LJ, Nichols E, Steiner TJ, et al. Global, regional, and national burden of migraine and tension-type headache,1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17: 954-76.

2. Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1211-59.

3. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia 2018; 38: 1-211.

4. Ashina M, Hansen JM, Do TP, Melo-Carrillo A, Burstein R, Moskowitz MA. Migraine and the trigeminovascular system — 40 years and counting. Lancet Neurol 2019; 18: 795-804.

5. Ashina M, Hansen JM, Á Dunga BO, Olesen J. Human models of migraine — short-term pain for long-term gain. Nat Rev Neurol 2017; 13: 713-24.

6. Stewart WF, Wood C, Reed ML, Roy J, Lipton RB. Cumulative lifetime migraine incidence in women and men. Cephalalgia 2008; 28: 1170-8.

7. Wöber C, Wöber-Bingöl Ç, Uluduz D, et al. Undifferentiated headache: broadening the approach to headache in children and adolescents, with supporting evidence from a nationwide school-based

cross-sectional survey in Turkey. J Headache Pain 2018; 19: 18.

8. Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting the Burden: the Global Campaign against Headache. J Headache Pain 2019; 20: 57.

9. Polderman TJC, Benyamin B, de Leeuw CA, et al. Meta-analysis of the heritability of human traits based on fifty years of twin studies. Nat Genet 2015; 47: 702-9.

10. Gormley P, Anttila V, Winsvold BS, et al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nat Genet 2016; 48: 856-66.

11. Olesen J, Burstein R, Ashina M, Tfelt-Hansen P. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol 2009; 8: 679-90.

12. Finucane HK, Reshef YA, Anttila V, et al. Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types. Nat Genet 2018; 50: 621-9.

13. Thomsen LL, Kruuse C, Iversen HK, Olesen J. A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. Eur J Neurol 1994; 1: 73-80.

14. Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia 2010; 30: 1179-86.

15. Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 2009; 132: 16-25.

16. Kruuse C, Thomsen LL, Birk S, Olesen J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 2003; 126: 241-7.

17. Guo S, Olesen J, Ashina M. Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase. Brain 2014; 137: 2951-9.

18. Armstead WM. Role of ATP-sensitive K+ channels in cGMP-mediated pial artery vasodilation. Am J Physiol 1996; 270: H423-H426.

19. Wellman GC, Quayle JM, Standen NB. ATP-sensitive K+ channel activation by calcitonin gene-related peptide and protein kinase A in pig coronary arterial smooth muscle. J Physiol 1998; 507: 117-29.

20. Al-Karagholi MA-M, Hansen JM, Guo S, Olesen J, Ashina M. Opening of ATP sensitive potassium channels causes migraine attacks: a new target for the treatment of migraine. Brain 2019; 142: 2644-54.

21. Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol 1984; 16: 157-68.

22. Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia 2007; 27: 394-402.

23. Lipton RB, Pavlovic JM, Haut SR, Grosberg BM, Buse DC. Methodological issues in studying trigger factors and premonitory features of migraine. Headache 2014; 54: 1661-9.

24. Hougaard A, Amin FM, Hauge AW, Ashina M, Olesen J. Provocation of migraine with aura using natural trigger factors. Neurology 2013; 80: 428-31.

25. Ploug KB, Amrutkar DV, Baun M, et al. K (ATP) channel openers in the trigemino vascular system. Cephalalgia 2012; 32: 55-65.

26. Al-Karagholi MA, Ghanizada H, Hansen JM, et al. Levcromakalim, an adenosine triphosphate-sensitive potassium channel opener, dilates extracerebral but not cerebral arteries. Headache 2019; 59: 1468-80.

27. Standen NB, Quayle JM, Davies NW, Brayden JE, Huang Y, Nelson MT. Hyperpolarizing vasodilators activate ATP-sensitive K+ channels in arterial smooth muscle. Science 1989; 245: 177-80.

28. Kullmann DM, Waxman SG. Neurological channelopathies: new insights into disease mechanisms and ion channel function. J Physiol 2010; 588: 1823-7.

29. Kremeyer B, Lopera F, Cox JJ, et al. A gain-of-function mutation in TRPA1 causes familial episodic pain syndrome. Neuron 2010; 66: 671-80.

30. Lassen LH, Ashina M, Christiansen I, Ulrich V, Olesen J. Nitric oxide synthase inhibition in migraine. Lancet 1997; 349: 401-2.

31. Høivik HO, Laurijssens BE, Harnisch LO, et al. Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia 2010; 30: 1458-67.

32. Palmer JE, Guillard FL, Laurijssens BE, Wentz AL, Dixon RM, Williams PM. A randomised, single-blind, placebo controlled, adaptive clinical trial of GW274150, a selective iNOS inhibitor, in the treatment of acute migraine. Cephalalgia 2009; 29: 124.

33. Ashina M, Doležil D, Bonner JH, et al.A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of AMG 301 in migraine prevention. Presented at the 13th European Headache Congress, Athens, May 30–June 1, 2019.

34. Moldovan Loomis C, Dutzar B, Ojala EW, et al. Pharmacologic characterization of ALD1910, a potent humanized monoclonal antibody against the pituitary adenylate cyclase-activating peptide. J Pharmacol Exp Ther 2019; 369: 26-36.

35. Dalkara T, Nozari A, Moskowitz MA. Migraine aura pathophysiology: the role of blood vessels and microembolisation. Lancet Neurol 2010; 9: 309-17.

36. Sanchez del Rio M, Bakker D, Wu O, et al. Perfusion weighted imaging during migraine: spontaneous visual aura and headache. Cephalalgia 1999; 19: 701-7.

37. Karatas H, Erdener SE, Gursoy-Ozdemir Y, et al. Spreading depression triggers headache by activating neuronal Panx1 channels. Science 2013; 339: 1092-5.

38. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002; 8: 136-42.

39. Amundsen S, Nordeng H, Nezvalová- Henriksen K, Stovner LJ, Spigset O. Pharmacological

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

CONTENIDOS RELACIONADOS
AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2022